Merck Launches Nexplanon Birth Control Implant
WHITEHOUSE STATION, N.J. November 9, 2011 (AP) - Drugmaker Merck & Co. said Wednesday it has launched the long-acting birth control implant Nexplanon in the United States.
The Whitehouse Station, N.J., company said Nexplanon is approved by the Food and Drug Administration for the prevention of pregnancy in women for up to three years. It is a soft medical polymer about the size of a matchstick inserted under the skin of a woman's arm during a minor surgical procedure.
Nexplanon does not contain estrogen. Etonogestrel, the progestin in it, prevents pregnancy.
Shares of Merck fell 5 cents in late-morning trading to $34.42, while the Dow Jones industrial average dropped nearly 2 percent.
Posted: November 2011